推荐产品
等级
pharmaceutical primary standard
API类
etidronate
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
InChI
1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2
InChI key
GWBBVOVXJZATQQ-UHFFFAOYSA-L
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Etidronate disodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
预防措施声明
危险分类
Acute Tox. 4 Oral
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Determination of etidronate disodium tablets by ion chromatography with indirect UV detection.
Tsai E W, et al.
Journal of Pharmaceutical and Biomedical Analysis, 11(6), 513-516 (1993)
S M Krane
Annals of internal medicine, 96(5), 619-625 (1982-05-01)
Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonates, and mithramycin. The pagetic lesion is not, however, cured. Etidronate disodium is one of the diphosphonates. The clinical improvement attained with
The role of risedronate in osteopenia in Crohn's disease.
Alice Buchan et al.
Gut, 64(1), 185-185 (2013-12-07)
Ivana Sestak et al.
The Lancet. Oncology, 15(13), 1460-1468 (2014-12-03)
Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are associated with accelerated bone loss. We assessed effectiveness of oral risedronate for prevention of reduction in bone mineral density (BMD) after 3 years of
Jörg Schilcher et al.
Acta orthopaedica, 86(1), 100-107 (2015-01-15)
Use of bisphosphonates in women is associated with higher risk of atypical femoral fractures. The risk in terms of timing of use and type of bisphosphonate, and in men, remains unclear. We reviewed radiographs of 5,342 Swedish women and men
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门